CDRH’s Mansfield Addresses Upcoming Drug/Dx Co-Development Guidance
This article was originally published in The Gray Sheet
Executive Summary
Either an IND or an IDE will be sufficient for companion diagnostic studies, a CDRH diagnostics official clarified last week. That is among the issues that will be addressed in an upcoming co-development draft guidance.
You may also be interested in...
FDA Companion, Co-Development Dx Guidances On Track, Official Says
FDA aims to issue both a final companion diagnostics guidance document and a separate draft guidance on the co-development of drugs and tests in the coming months.
Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report
A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.
Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report
A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.